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NF-1 is associated with a 15-year decrease in life expectancy. Internal neurofibromas are associated with increased
morbidity and mortality through malignant transformation and compression of neighboring organs. Our purpose
was to develop and to validate a clinical score for predicting internal neurofibromas in adults. The development
sample comprised 208 patients and the validation sample 191 patients. The score was developed using logistic
regression. Discrimination and calibration of the model were evaluated. Four variables were independently
associated with internal neurofibromas: at least two subcutaneous neurofibromas (odds ratio (OR)¼ 4.7,
[2.1–10.5]), agep30 years (OR¼ 3.1, [1.4–6.8]), absence of cutaneous neurofibromas (OR¼ 2.6, [0.9–7.5]), and fewer
than six cafe´-au-lait spots (OR¼ 2.0 [0.9–4.6]). The score computed by linear combination of the rounded
coefficients of these four variables ranged from 0 to 40 (mean, 12.8±10.8). The probability of internal
neurofibromas was computed as exp (2.93þ 0.11Score)/exp (1þ (2.93þ 0.11Score)). Probabilities agreed well
with the observed frequencies indicating good calibration, and discrimination was adequate (AUC-ROC, 0.75) in
both data sets. The presence of internal neurofibromas can be accurately predicted using a simple clinical score.
Further work will establish the score threshold that identifies patients at high risk for complications.
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INTRODUCTION
Neurofibromatosis-1 (NF-1 [MIM 162,200]) is a common
autosomal dominant disorder that is associated with both
morbidity and mortality (Rasmussen et al., 2001). Internal
neurofibromas are among the main causes of adverse
outcomes (Tucker et al., 2005). These tumors may cause
spinal cord compression, and about 10% of them undergo
transformation to malignant peripheral nerve-sheath tumors
(MPNSTs), which are among the main causes of death in
adults with NF-1 (Rasmussen et al., 2001). Internal neurofi-
bromas arise from the spinal nerve roots and may extend into
surrounding structures to involve multiple fascicles and
branches. They are generally asymptomatic (Tonsgard et al.,
1998), being identified only upon imaging studies. Accurate
data can be obtained using magnetic resonance imaging
(MRI), which shows large diffuse paraspinal tumors with high
signal intensity on T2-weighted and T2 fat-saturation images
contrasting with normal or, more often, low signal intensity
on T1-weighted images (Drouet et al., 2004; Mautner et al.,
2006). Clinical indicators of malignancy are persistent or
increasing pain, enlargement of the tumor, and neurological
deficiencies (Valeyrie-Allanore et al., 2005). MPNSTs carry a
poor prognosis. Diagnosis is often delayed, as imaging studies
are not performed routinely as part of the follow-up of patients
with NF-1. Consequently, metastatic spread is common and
survival is limited. The main prognostic factor may be tumor
size, which governs the chances of curative surgery (Doorn
et al., 1995). Therefore, an early diagnosis is a principal
objective. As MPNSTs develop from internal neurofibromas, a
score predicting the presence of internal neurofibromas might
improve the early diagnosis of MPNSTs, as close monitoring
could be offered to patients with high-risk score values.
The purpose of this study was to develop a clinical score
for predicting the presence of internal neurofibromas in
patients with NF-1 and to assess its performance by
evaluating discrimination and calibration.
See related commentary on pg 2167
& 2010 The Society for Investigative Dermatology www.jidonline.org 2173
ORIGINAL ARTICLE
Received 7 October 2009; revised 16 February 2010; accepted 13 March
2010; published online 29 April 2010
1Universite Paris 12, LIC EA4393 (Laboratoire d’Investigation Clinique),
Cre´teil, France; 2Poˆle Recherche Clinique-Sante´ Publique, AP-HP, Hoˆpital
Henri Mondor, Cre´teil, France; 3Service de Dermatologie, AP-HP, Hoˆpital
Henri Mondor, Cre´teil, France; 4Centre de Re´fe´rence des Neurofibromatoses,
AP-HP, Hoˆpital Henri Mondor, Cre´teil, France; 5Re´seau NF-Ile-de-France,
France; 6Service de Neurope´diatrie, AP-HP, Hoˆpital Armand Trousseau, Paris,
France; 7UPMC Universite´ Paris 06, Paris, France; 8Service de Dermatologie,
Centre MAGEC, AP-HP, Hoˆpital Necker—Enfants Malades, Paris, France;
9Faculte´ de Me´decine Paris 5, Paris, France; 10INSERM, Centre d’Investigation
Clinique 006, AP-HP, Hoˆpital Henri-Mondor, Cre´teil, France; 11Service de
Dermatologie, Hoˆpital l’Archet 2, Nice, France; 12Service de Pe´diatrie,
Institut Calot, Berck Hoˆpital Central, Berck, France; 13Service de Neurologie,
Nancy, France and 14Service de Dermatologie, Hoˆpital Nord, Marseille,
France
Correspondence: Sylvie Bastuji-Garin, Service de Sante´ Publique, Hoˆpital Henri-
Mondor, Cre´teil Cedex 94010, France. E-mail: sylvie.bastuji-garin@hmn.aphp.fr
Abbreviations: AUC-ROC, area under the receiver-operating characteristic
curve; CI, confidence interval; MPNSTs, malignant peripheral nerve-sheath
tumors; MRI, magnetic resonance imaging; NF-1, neurofibromatosis type-1;
OR, odds ratio; ROC, receiver-operating characteristic
RESULTS
Study populations
The characteristics of the development and validation
samples are reported in Table 1. The development sample
comprised 208 patients, 122 females (59%), and 86 males
with a mean age of 41.10 (±13) years (range, 20–78). Internal
neurofibromas were present in 46 (22%) patients. The
validation sample was composed of 191 patients, 108
females (57%), and 83 males with a mean age of 40.3
(±13) years (range 17–72), of whom 39 (20%) were classified
as having internal neurofibromas. There were 304 patients
whose internal neurofibroma status was unknown and who
therefore were not included in the validation sample; their
characteristics were not significantly different from those of
the validation sample (data not shown).
Model development
In the univariate analyses, five variables were associated, or
nearly associated, with internal neurofibromas: age p30
years, at least two subcutaneous neurofibromas, fewer than
six cafe´-au-lait spots, absence of cutaneous neurofibromas,
and absence of freckles (Table 2). No significant interaction
was observed between these parameters. Absence of freckles
was strongly associated with the other variables and was not
independently associated with internal neurofibromas in
the multivariate analysis. The four remaining variables
were independently associated with internal neurofibromas
(Table 3). Calibration was excellent (Hosmer–Lemeshow
statistic¼2.4; df¼4; P¼ 0.66) and discrimination was good
(area under the receiver–operating characteristic curve (AUC-
ROC)¼ 0.75; 95% confidence interval (CI), 0.7–0.8). The
b-coefficients derived from the four independent predictors
were multiplied by 10 and rounded to the nearest integer
(Table 3). Loss-of-fit related to the rounded coefficients
was negligible (Hosmer–Lemeshow statistic ¼4.5; df¼ 7;
P40.5). Discrimination was similar (AUC-ROC¼0.75; 95%
CI, 0.68–0.82). Table 4 shows the sensitivity and the
specificity of the different cut-off levels of the score in the
development sample. False-positive and false-negative
rates can be deducted from sensitivity and specificity
(1 – specificity and 1 – sensitivity, respectively). The score
was then computed by means of a linear combination of the
rounded coefficients: Score¼ 10  (age p30 years)þ10  (ab-
sence of cutaneous neurofibroma)þ15  (X2 subcutaneous
neurofibromas)þ 5  (o6 cafe´-au-lait spots). Each factor was
assigned the value 1 if present or 0 if absent. Therefore, the
score could range from 0 to 40. The mean score was 12.8
(±10.8). An equation based on the logistic regression model
was developed to convert the score into a probability of
having internal neurofibromas in the following manner: exp
(2.93þ 0.11*Score)/exp (1þ (2.93þ 0.11*Score)).
Model assessments
Internal validation. The shrinkage coefficients obtained by
bootstrapping methods were similar to those based on the
logistic regression model: a0 ¼a* 1.05 and b0 ¼ b*0.98.
External validation. The score maintained adequate discri-
mination and calibration (Hosmer–Lemeshow statistic¼12.7;
df¼9; P¼ 0.2; AUC-ROC¼0.73) when it was applied to
each member of the validation sample. Table 5 shows
the predicted risk of internal neurofibromas for each
possible score.
DISCUSSION
Our study shows that easily recognizable clinical features can
be used to predict the risk of internal neurofibromas among
adults with NF-1. Four factors were independently associated
with internal neurofibromas: at least two subcutaneous
neurofibromas, absence of cutaneous neurofibromas, fewer
than 6 cafe´-au-lait spots, and age p30 years. The NF-1Score
was computed as follows: 10 (age p30 years)þ 10 (absence
of cutaneous neurofibromas)þ 15 (X2 subcutaneous neu-
rofibromas)þ5 (o6 cafe´-au-lait spots). This score had
excellent calibration and good discrimination.
Special attention was given to selecting the development
sample. Our goal was to select a population of NF-1 patients
systematically investigated with MRI, as this method is
highly reliable for detecting internal neurofibromas. As part
of the case–control study that included the patients in the
development sample, the MRI data were reviewed by senior
radiologists who were masked to the clinical features, to
minimize assessment bias. Furthermore, the prevalence of the
various clinical features in the development sample was
Table 1. Characteristics of the patients with NF-1
included in the development (n=208) and validation
(n=191) samples
Clinical feature
Development sample
n=208
Validation sample
n=191
Female gender 122 (59) 108 (57)
Age p30 years 48 (23) 46 (24)
Familial case 112 (54) 127 (67)
X2 Subcutaneous
neurofibromas
106 (51) 111 (61)
No cutaneous
neurofibromas
19 (9) 30 (16)
Plexiform neurofibromas 114 (55) 95 (50)
o6 Cafe´-au-lait spots 43 (21) 58 (30)
No freckles 39 (19) 31 (16)
Scoliosis 87 (42) 90 (47)
Pseudarthrosis 6 (3) 6 (3)
Headache 79 (38) 77 (40)
Epilepsy 4 (2) 8 (4)
Hydrocephalus 3 (1) 7 (4)
Learning disabilities 109 (52) 98 (51)
Facial asymmetry 20 (10) 13 (7)
Hypertension 17 (8) 23 (12)
Internal neurofibroma 46 (22) 39 (20)
Abbreviation: NF-1, neurofibromatosis-1.
The data are the numbers of patients (%).
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consistent with those previously reported in NF-1 patients
(Friedman and Birch, 1997), indicating that the development
sample was representative of NF-1 patients. A cohort study
design is generally used to assess predictors to minimize
information bias (Coste et al., 1996). However, NF-1 is a rare
disease and routine MRI screening is not recommended in
everyday clinical practice (Pinson et al., 2001). By taking the
development sample from a case–control study in which all
patients underwent MRI, we improved the reliability of internal
neurofibroma diagnosis as compared with a cohort study.
The validation sample was composed of patients included
in the Re´seau NF-France database. Selection bias seems
unlikely, as the prevalences of NF-1 features were consistent
with those reported previously in other populations of NF-1
patients (Friedman and Birch, 1997). Furthermore, the
features in non-included patients whose internal neurofibro-
ma status was unknown were similar to those in the
validation sample. However, absence of routine MRI or
computed tomography in the validation sample may con-
stitute a limitation of our study. MRI or computed tomo-
graphy was performed only when routine imaging studies
(chest radiograph and abdominal sonogram) or clinical
symptoms suggested the presence of internal neurofibromas.
This may have resulted in verification bias. Furthermore, we
had no data on the size or location of internal neurofibromas
in the validation sample.
To validate the NF-1Score, we used a rigorous procedure
involving both internal validation (shrinkage) and external
validation. Shrinkage of the regression coefficients (a and b)
to correct for over-optimism in the model may help to make
Table 2. Univariate analysis in the development sample (n=208) of factors suspected to be associated with internal
NFs
Internal neurofibroma
No (n=162) Yes (n=46) Odds ratio (95% CI)1 P-value2
Female gender 97 (60) 25 (58) 1.3 (0.6–2.4) 0.502
Age p30 years 30 (18) 18 (39) 2.8 (1.4–5.9) 0.0043
Familial cases 88 (54) 24 (52) 0.9 (0.5–1.8) 0.800
X2 Subcutaneous neurofibromas 70 (43) 36 (78) 4.7 (2.1–10.6) o10–4 3
No cutaneous NF 9 (6) 10 (22) 4.7 (1.7–12.8) 0.0013
Plexiform NF 90 (56) 24 (52) 0.9 (0.5–1.7) 0.684
o6 Cafe´-au-lait spots 28 (17) 15 (33) 2.3 (1.1–4.9) 0.0243
No freckles 26 (16) 13 (28) 2.1 (0.9–4.5) 0.0613
Scoliosis 68 (42) 19 (41) 1.0 (0.5–1.9) 0.935
Pseudarthroseis 4 (2) 2 (4) 1.8 (0.3–10.2) 0.502
Headache 59 (36) 20 (43) 1.3 (0.7–2.6) 0.385
Epilepsy 2 (1) 2 (4) 3.6 (0.5–26.9) 0.175
Hydrocephalus 3 (2) 0 0 0.353
Learning disabilities 83 (51) 26 (57) 1.2 (0.6–2.4) 0.527
Facial asymmetry (n=122/78) 12 (10) 5 (6) 0.6 (0.21–1.87) 0.397
Hypertension 13 (8) 4 (9) 1.1 (0.3–3.5) 0.883
Abbreviations: CI, confidence interval; NF, neurofibromatosis.
1Odds ratios with their 95% CIs were estimated using logistic regression.
2P-value by w2-test or Fisher’s exact test, as appropriate.
3Variables yielding P-values less than 0.15 were entered into a multiple logistic regression model.
The data represent the numbers of patients (%).
Table 3. Factors independently associated with internal NFs in the multivariate analysis in the development sample
(n=208)
Odds ratio 95% CI1 P-value b-Coefficient2 Points
Age p30 years old 3.1 1.4–6.8 0.006 1.12 10
No cutaneous neurofibromas 2.6 0.9–7.5 0.08 0.95 10
X2 Subcutaneous neurofibromas 4.7 2.1–10.5 o104 1.55 15
o6 Cafe´-au-lait spots 2.0 0.9–4.6 0.08 0.71 5
Abbreviations: CI, confidence interval; NF, neurofibromatosis.
1Confidence interval.
2b-Coefficients of the factors independently associated with internal neurofibromas.
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models more transferable (Steyerberg et al., 2004). The results
of our internal and external validations in an independent
sample indicated satisfactory performance, with good cali-
bration and discrimination. Therefore, from a methodological
point of view, this score could be considered as a good
prediction tool. Although such probability models cannot be
used reliably to predict outcome in individual patients, the
information provided by such models using easily recogniz-
able clinical features could be useful for clinical decision-
making. For instance, a probability of 0.56 (NF-1Score¼30)
means that approximately 56 out of 100 patients with this
score would be expected to have internal neurofibromas.
One cannot say whether any specific individual patient will
be one of the 56 patients who may have internal neurofi-
bromas or one of the 44 such patients who may have not.
Clinicians often have to discuss whether or not an imaging
would be useful. That is, which NF-1 patients need MRI to
detect asymptomatic MPNTs. Thus, although MRI is not
systematically recommended, faced with a patient with a
high NF-1Score value, physicians would be alerted and
mandate a radiological follow-up. Whether systematic
radiological investigations are required to evaluate the
potential risk of MPNTs in this new population at risk
remains to be investigated. Furthermore, introduction of new
treatment is usually preceded by the demonstration of its
effectiveness in a controlled trial. An important aspect of the
conduct of such trials is the ability to define and control the
severity-of-illness of the patients studied.
In choosing the appropriate ‘‘cut-off’’ score that defines high
risk, there is a trade-off between a score that confers high
sensitivity or high specificity. A high cut-off score that gave high
specify would lose sensitivity, thereby missing many patients
who have internal neurofibromas. However, a low score, with
high sensitivity, might select too many patients as high risk,
which would be of no practical benefit. Therefore, different
thresholds should be defined according to the clinical purpose.
Subcutaneous neurofibromas were independently asso-
ciated with internal neurofibromas in our study, in keeping
with earlier data (Tucker et al., 2005). Furthermore, patients
with subcutaneous neurofibromas were at higher risk for
mortality in two different NF-1 populations, from France
(Khosrotehrani et al., 2003) and North America (Khosroteh-
rani et al., 2005), respectively. None of the other three factors
identified in our study have been reported previously to be
associated with internal neurofibromas. However, the asso-
ciation linking absence of cutaneous neurofibromas to
internal neurofibromas is in agreement with a previous study
in which mortality was higher among NF-1 patients who had
no cutaneous neurofibromas (Khosrotehrani et al., 2003). The
association between the presence of internal neurofibromas
and age younger than 30 years is consistent with a report that
most MPNSTs may develop from pre-existing internal
neurofibromas, with the risk being highest at about 30 years
of age (Evans et al., 2002). Conversely the association
between presence of internal neurofibromas and fewer than
six cafe´-au-lait spots has never been reported even though
four individuals with multiple spinal tumors and no cafe´-au-
lait spots but with NF-1 mutation have been identified
(Kaufmann et al., 2001). The two features in the score,
namely, absence of cutaneous neurofibromas and fewer
than six cafe´-au-lait spots, are unusual in NF-1 patients.
Presence of at least two neurofibromas of any type and at
least six cafe´-au-lait spots are the diagnostic criteria for NF-1.
However, all the patients in our study had a definitive
diagnosis of NF-1. In patients younger than 30 years, the
combination of internal neurofibromas, fewer than six cafe´-
au-lait spots, no cutaneous neurofibromas, and at least two
subcutaneous neurofibromas constitutes a phenotype that is
both distinct from classical NF-1 and particularly severe.
Recently, examination of the phenotypic correlations be-
tween affected relatives in 750 NF-1 patients from 275
multiplex families collected through the NF-France Network
provided evidence that genetic modifiers, unlinked to the NF-1
Table 4. Sensitivity and specificity values of the
different cut-off levels of the NF-1Score obtained in
the development sample
Development sample
(n=208) AUC–ROC=0.75
Cut-point Sensitivity (%) Specificity (%)
X0 100 0
X5 91 37
X10 87 43
X15 80 53
X20 50 83
X25 41 91
X30 26 98
X35 11 99
X40 2 100
Abbreviations: AUC–ROC, area under the receiver–operating character-
istic curve; NF-1, neurofibromatosis-1.
Table 5. Probabilities of the presence of internal NFs
according to the NF-1Score level in the validation
sample (191 patients)
Probability of
having internal
Internal
neurofibromas
(n=39)
No internal
neurofibromas
(n=152)
neurofibromas NF-1Score Observed Expected Observed Expected
0.051 0 3 2.0 36 37.0
0.083 5 2 1.1 11 11.9
0.133 10 3 1.7 10 11.3
0.207 15 6 11.6 50 44.4
0.308 20 8 8.0 18 18.0
0.430 25 7 9.5 15 12.5
0.561 30 3 5.1 6 4.0
0.684 35 2 4.1 4 1.9
0.787 40 5 5.5 2 1.5
Abbreviation: NF-1, neurofibromatosis-1.
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locus, contribute to the variable expressivity of the disease
(Sabbagh et al., 2009). However, biological factors that
influence the NF-1 risk of morbidity–mortality are not known.
In sum, we developed a simple scoring system (the
NF-1Score) that accurately predicted the presence of internal
neurofibromas in patients with NF-1. The NF-1Score could
be used to identify NF-1 patients who require particularly
close monitoring for internal neurofibromas.
MATERIALS AND METHODS
Population and study samples
Patients meeting the diagnostic criteria for NF-1 established at the
National Institutes of Health Consensus Development Conference
(Conference statement, 1988) were included prospectively by the
French NF network (Re´seau NF-France). We used two samples for our
study. The development sample, used to develop the prediction score,
comprised 208 adults (17 years or older) included in an ongoing
prospective multicenter case–control study (begun in 2005) designed
to assess whether subcutaneous neurofibromas were associated with
several types of internal neurofibromas. All patients in this sample
were carefully investigated by MRI to determine with confidence
whether internal neurofibromas were present. The validation sample
was composed of the 191 NF-1 patients who were prospectively
included in the Re´seau NF-France database from June 2003 to June
2008, and who met the following criteria: 17 years or older, probands
or sporadic disease, known internal neurofibroma status, and non-
inclusion in the above-mentioned case–control study (Figure 1). The
study was approved by the institutional review boards of Iˆle-de-France
IV (Paris, France) and informed consent was obtained from all
patients. The study adhered to the Declaration of Helsinki Principles.
Data collection
Demographic information (age and sex) and clinical features
recorded in the databases were collected during routine clinical
assessments at neurofibromatosis clinics (Table 1). Detailed informa-
tion was available on the dermatological characteristics: number of
cafe´-au-lait spots (0, 1, 2, 3, 4, 5, 6, X7), number of cutaneous
neurofibromas (0, 1, 2–9, 10–99, X100), number of subcutaneous
neurofibromas (0, 1, 2–9, 10–99,X100), and number and location of
plexiform neurofibromas. Among clinical features, we selected those
known to be associated with mortality: absence of cutaneous
neurofibromas, facial asymmetry, at least two subcutaneous
neurofibromas, and male gender (Khosrotehrani et al., 2003,
2005). We recorded the following features as present or absent:
orthopedic complications (scoliosis and pseudarthrosis), neurologi-
cal abnormalities (headache, epilepsy and learning disabilities),
hypertension, and renal artery stenosis.
Classification of patients: identification of internal
neurofibromas
All patients in the development sample underwent standardized
MRI of the spinal cord and nerve roots using non-contrast-enhanced
T1- and T2-weighted sequences (coronal plane) and short-tau
inversion-recovery (STIR) sequences. Paraspinal neurofibromas were
characterized as diffuse or focal and aso3 orX3 cm. Patients were
classified as having internal neurofibromas if they had at least one
diffuse paraspinal neurofibroma or at least one focal paraspinal
neurofibroma measuring at least 3 cm. Patients with neither criterion
were classified as not having internal neurofibromas (Drouet et al.,
2004; Mautner et al., 2006).
In the validation sample, MRI was not performed routinely (Pinson
et al., 2001). MRI or computed tomography is usually recommended
when there is evidence of internal neurofibromas on other imaging
studies (chest radiograph or abdominal sonogram) or when symptoms
such as pain or neurological deficits suggest internal neurofibromas.
Patients in the validation sample were classified as having internal
neurofibromas when the variable ‘‘paraspinal neurofibromas’’ was
coded ‘‘yes’’ in the database and as not having internal neurofibromas
when this variable was coded ‘‘no’’. No information was available on
the size or location of internal neurofibromas in the validation sample.
Statistical analysis
Data were analyzed using STATA software version 8 (Stata, College
Station, TX). All tests were two-tailed and P-values no greater than
Patients included in the Réseau NF-France: n=1,700
Diagnosis of NF1 according to established clinical criteria
n=1,099
No NF1, n=601 
Patients 17 years or older: n=748
Younger than 17 years: n=351
Familial cases: n=233
Probands or sporadic cases: n=515
Internal NF status known: n=211
Internal NF status unknown: n=304
191 Patients included in the validation sample
Patients included in the development sample: n=20
Figure 1. Flow chart of the validation sample.
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0.10 were considered for prognostic modeling (Steyerberg et al.,
2000). The characteristics of the development and validation
samples were described. The characteristics of the patients who
were not included in the validation sample because their internal
neurofibroma status was unknown, were compared to those of the
patients included in the validation sample. Quantitative variables are
either reported as median±SD or converted to categorical variables.
Thus, age was dichotomized according to the peak MPNST
incidence in NF-1 patients (o30 or X30 years) (Evans et al.,
2002). Qualitative variables are reported as number (%).
Model development
The characteristics of patients with and without internal NF were
compared in univariate analyses using the w2-test or Fisher’s exact
test, as appropriate. Odds ratios (ORs) were estimated with their 95%
CIs, using logistic regression models. Two-by-two analyses were also
performed to assess potential interactions and confounding by fitting
multiplicative models. Variables yielding P-values less than 0.15 in the
univariate analyses were entered into a multiple logistic regression
model. The final model included the variables independently
associated with the presence of internal neurofibromas. Performance
of the model, including calibration and discrimination, was evaluated
by computing the Hosmer–Lemeshow statistic (Hosmer and Leme-
show, 1989) and the AUC-ROC (Hanley and McNeil, 1982),
respectively. The Hosmer–Lemeshow test evaluates whether the
predicted probabilities agree with the observed probabilities. Dis-
crimination is the ability to distinguish patients with internal
neurofibromas from those without internal neurofibromas.
Then, we used the variables identified by the multivariate
analysis to build a simple-to-use score for predicting the presence
of internal neurofibromas. Points were assigned to each variable on
the basis of the regression coefficients in the final model: the
b-coefficient was multiplied by 10 and the result was rounded to the
nearest integer (Le Gall et al., 1993). We checked whether the
predictive performance of these rounded coefficients was similar to
that of the original coefficients. The score was calculated for each
patient and a multiple logistic regression equation was used to
convert the score into a probability of having internal neurofibromas:
the logit (aþ bScore) was computed and the probability was then
estimated as P¼ elogit/(1þ elogit).
Model assessments
Internal validation. As the development sample comprised only
208 patients, we used bootstrapping to estimate shrinkage coefficients
(van Houwelingen and Le Cessie, 1990) to avoid over-optimism (Miller
and Hui, 1991; Steyerberg et al., 2004) and to obtain nearly unbiased
estimates of the predictive accuracy of the model (Harrell et al., 1996).
We drew 1,000 samples at random. The logistic regression coefficients
were re-estimated in the bootstrap samples.
External validation. Performance of the model, including calibra-
tion and discrimination, was assessed in the validation sample.
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